0000899243-20-021598.txt : 20200806 0000899243-20-021598.hdr.sgml : 20200806 20200806060949 ACCESSION NUMBER: 0000899243-20-021598 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leen Ann M. CENTRAL INDEX KEY: 0001763026 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 201079632 MAIL ADDRESS: STREET 1: 5 WEST FORSYTH STREET STREET 2: SUITE 200 CITY: JACKSONVILLE STATE: FL ZIP: 32202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0001754068 Allovir, Inc. ALVR 0001763026 Leen Ann M. C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2020-08-03 4 C 0 2436773 A 2436773 I See Footnote Common Stock 60394 D Series A-3 Convertible Preferred Stock 2020-08-03 4 C 0 3631293 D Common Stock 2436773 0 I See Footnote Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. Shares held by Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Brett Hagen, as Attorney-in-Fact 2020-08-05